Ed Ikeguchi, M.D. Named AiCure’s First President
Founder and Board member Adam Hanina Assumes Role as Head of Special Projects
NEW YORK, Jan. 28, 2020 – AiCure, recognized as one of the world’s 100 most innovative artificial intelligence companies, announced changes in leadership, including the creation of a new role of president, as part of a well-defined strategic planning process that was initiated five years ago. As AiCure’s first President, Ed Ikeguchi, M.D. will increase his daily operational duties and responsibilities and continue to serve as AiCure’s Chief Medical Officer (CMO). Before joining AiCure in mid-2018, Dr. Ikeguchi was co-founder, CEO and CMO at Medidata Solutions for nearly a decade, where he grew the company from its inception to its initial public offering in 2009.
The appointment of a president allows AiCure founder Adam Hanina, who has served as CEO since inception, to focus on and guide special projects that aim to have high-level impact on future growth.
“I am extremely proud of the tremendous growth that AiCure has achieved since inception. We are evolving as a data company driving continuous innovation,” said Adam Hanina. “This is an exciting inflection point and we’re poised to grow at a faster rate. It is my privilege to hand the baton over to Ed who has transformed an exceptional company into a market-leading data powerhouse – I’m looking forward to seeing him do it again.”
“I am honored to lead us to the next level as an AI and advanced data analytics company,” Dr. Ikeguchi said, “I believe in the future of AiCure where there are so many parallels that are evident to what I have previously experienced.”
About AiCure
AiCure is an AI and advanced data analytics company targeting the healthcare industry. AiCure uses artificial intelligence to see, hear and understand how people respond to treatment across clinical trials and patient care. Clinically proven to accurately measure and modify patient behavior, AiCure’s technologies keep patients engaged and optimized to treatment, as well as assess treatment effectiveness.
Founded in 2010 and funded by the National Institutes of Health (NIH) and leading institutional investors, AiCure has more than 110 patents filed and works with global clients in over 30 countries. AiCure is globally recognized and a recipient of the Scrip Award, AI 100 and Digital Health 150. For more information, please visit www.aicure.com and follow our progress on LinkedIn and on Twitter @AiCure.
Contact information:
Mario R. Nacinovich Jr., MSc
Global Head, Communications and Marketing
AiCure
19 West 24th Street, 11th Floor
NY, NY 10010
www.aicure.com
mario.nacinovich@aicure.com
M + 1 917 710 7322